Aurobindo Pharma has completed its acquisition of Lannett Company, Inc., finalizing a deal that significantly expands the Indian generic drugmaker's presence in the United States.
The transaction, which was previously announced, saw Aurobindo take full ownership of the US-based entity from Lannett Seller Holdco, Inc., marking a strategic consolidation in the competitive generics sector.
The deal received the necessary regulatory clearance on June 18, 2026, when the US Federal Trade Commission approved the acquisition.
This green light allowed the transaction to proceed to closing, removing a key hurdle that often delays cross-border pharmaceutical mergers.
The FTC's approval suggests regulators viewed the combination as not posing significant antitrust concerns in the relevant therapeutic areas.
Lannett Company is a well-established player in the US generic pharmaceutical market, known for its manufacturing capabilities and portfolio of essential medications.